CONSTELLA

This brand name is authorized in Austria, Canada, Croatia, Estonia, Finland, Ireland, Lithuania, Netherlands, New Zealand, Poland, Spain, UK.

Active ingredients

The drug CONSTELLA contains one active pharmaceutical ingredient (API):

1	Linaclotide UNII N0TXR0XR5X - LINACLOTIDE
	Linaclotide is a Guanylate Cyclase-C receptor agonist (GCCA) with visceral analgesic and secretory activities. Through its action at GC-C, linaclotide has been shown to reduce visceral pain and increase GI transit in animal models and increase colonic transit in humans.
	Read more about Linaclotide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CONSTELLA Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A06AX04		A Alimentary tract and metabolism → A06 Laxatives → A06A Laxatives → A06AX Other laxatives
Discover more medicines within A06AX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02417162, 02417170, 02469510
EE	Ravimiamet	1603606, 1603617, 1603628, 1603639, 1744040
ES	Centro de información online de medicamentos de la AEMPS	112801002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	446436, 530276
GB	Medicines & Healthcare Products Regulatory Agency	219676
LT	Valstybinė vaistų kontrolės tarnyba	1068549, 1068550, 1068552, 1083935
NL	Z-Index G-Standaard, PRK	127043
NZ	Medicines and Medical Devices Safety Authority	19835, 19836, 19837
PL	Rejestru Produktów Leczniczych	100125023